* - Tentative Dates
The Company intends to utilize the Net Proceeds from the Issue towards funding of the following objects:
Kilitch Drugs (india) Ltd.'s revenue increased by 28% and profit after tax (PAT) rose by 84% between the financial year ending with March 31, 2025 and March 31, 2024.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 |
| Revenue | 198.32 | 154.37 |
| Profit After Tax | 24.94 | 13.58 |
| Net Worth | 202.33 | 176.29 |
| Reserves and Surplus | 186.25 | 160.21 |
| Amount in ₹ Crore | ||
Kilitch Drug manufactures and exports pharmaceutical formulations. The company develops, manufactures, and markets a wide range of injectables, oral solids, nutraceuticals, ophthalmic products, cosmetics, nutritional supplements, etc. It serves over 38+ countries and have facilities in India and Ethiopia.
The company is planning to launch a new plant for manufacturing diabetes, weight-loss drugs, and biosimilars with US-FDA and EU approvals.